Curium US
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Curium US sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Curium US: 4 sponsored US clinical trials, 1 recruiting.
Curium US sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 3 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastasis From Malignant Tumor of Prostate (Disorder), with 1 trials.
Upper-quartile sponsor footprint
Curium US sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
NCT05204927
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
NCT06235099
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
NCT05653856
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
Where Curium US enrollment is open (later-stage tilt)
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase mix: 3 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Metastasis From Malignant Tumor of Prostate (Disorder) (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Curium US: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Curium US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Curium US page
4 registered trials is a research-attention snapshot, not an endorsement of Curium US or any single study.
- 1 of Curium US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metastasis From Malignant Tumor of Prostate (Disorder) is the condition Curium US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastasis From Malignant Tumor of Prostate (Disorder) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Curium US pipeline card: 4 registered trials from official public datasets.Report a data error.